Selective Crystallization of a Novel Polymorph

Case study

When success in early trials creates a demand for new batches of API, the emergence of an unexpected polymorph can be a major setback to meeting critical clinical timelines. In this case study, we look at how Cambrex applied rigorous characterization standards and expert knowledge of critical water activity to isolate a previously undiscovered and uncharacterized polymorph for our client while supplying the original polymorph to maintain production for an ongoing clinical trial.

To learn how Cambrex approached, and ultimately solved, our client’s challenges, download the full case study.